Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Hyoscine Butyl Bromide for Management of Prolonged Labor

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nuoroda įrašoma į mainų sritį
Statusas
Rėmėjai
Ain Shams University
Bendradarbiai
Armed Forces Hospitals, Southern Region, Saudi Arabia

Raktažodžiai

Santrauka

To determine the value of using Hyoscine as an antispasmodic drug for the management of prolonged labor in nulliparous women at term.

apibūdinimas

Management of prolonged labor represents a challenging area in the daily obstetric practice. In 1993, Handa and Laros defined the arrest of active phase of labor, as failure of labor progress for 2 hours or more, and in 1994, WHO has proposed labor management partograph in which protraction is defined as < 1cm/hour cervical dilatation for a minimum of 4 hours.

Prolong labor increase the risks of maternal exhaustion, postpartum hemorrhage, sepsis, fetal distress and admission to the neonatal intensive care unit. The treatment of prolonged labor is highly desirable goal of intrapartum care, both from prospective of maternal and fetal wellbeing and for the provider of the birth services. Management of prolonged labor entails shorter exposure to pain, anxiety, and stress, and would thus translate into a major improvement in maternal satisfaction with child birth experience.

Several methods have been used for management of prolonged labor including amniotomy and oxytocin. Amniotomy can cause infection, and can be combined with oxytocin for better results while oxytocin can cause uterine hyper stimulation, water intoxication, vomiting, diarrhea, fetal distress, and neonatal jaundice.

Use of antispasmodics for reducing the duration of labor was first described in 1937 by Hirsch, who reported a decrease in labor length by two to four hours following intrapartum administration of an antispasmodic like drug (Syntropan®), mainly among older nulliparous, this was followed by many studies that investigated the role of antispasmodics in prevention of prolonged labor, however none of the these studies assessed the value of the antispasmodic for the treatment of prolonged labor; a recent Cochrane review advised that a rigorously designed well conducted randomized controlled trial with a large sample size would be beneficial to answer the question.

Hyoscine butyl bromide is spasmolytic drug that act by competitive antagonism to acetyl choline at post ganglionic parasympathetic nerve ending. It is claimed to reduce duration of labor by accelerating cervical dilatation without major side effects. It reduces the spasm of the smooth muscles. Although the efficacy of Hyoscine has been proven in various studies there is no clear evidence to recommend their routine use in management of prolonged labor.

The objective of the current study is to determine the use of Hyoscine as an antispasmodic drug for the management of prolonged labor in nulliparous women at term, managed according to a standard intrapartum protocol.

Datos

Paskutinį kartą patikrinta: 02/28/2017
Pirmasis pateikimas: 05/10/2013
Numatytas registravimas pateiktas: 05/13/2013
Pirmas paskelbtas: 05/14/2013
Paskutinis atnaujinimas pateiktas: 03/08/2017
Paskutinis atnaujinimas paskelbtas: 03/09/2017
Faktinė studijų pradžios data: 01/31/2014
Numatoma pirminio užbaigimo data: 03/31/2017
Numatoma studijų užbaigimo data: 05/31/2017

Būklė ar liga

Prolonged Labor

Intervencija / gydymas

Drug: Group A

Drug: Group B

Fazė

Fazė 3

Rankų grupės

RankaIntervencija / gydymas
Active Comparator: Group A
Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
Drug: Group A
Placebo Comparator: Group B
Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
Drug: Group B

Tinkamumo kriterijai

Amžius, tinkami studijuoti 18 Years Į 18 Years
Tinkamos studijoms lytysFemale
Priima sveikus savanoriusTaip
Kriterijai

Inclusion Criteria:

- Nulliparous women.

- Prolonged labor defined as no progress of labor for 2 hours or more.

- Gestational age ≥ 37 weeks.

- Singleton pregnancy.

- Cephalic presentation.

- Cervical dilatation ≥ 5 cm.

- Intact fetal membranes.

- No evidence of maternal or fetal distress.

- Average size baby.

Exclusion Criteria:

- Multigravid women.

- Multifetal pregnancy.

- History of cervical surgery.

- Blood pressure > 150/90 mmHg.

- Mal-presentation and mal-positions.

- Hypersensitivity to Hyoscine.

- Contraindication for vaginal delivery.

Rezultatas

Pirminės rezultatų priemonės

1. Caesarean section rate for failure to progress [6 hours]

Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge